HeXun Biosciences Co., Ltd. (TPEX:6986)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
60.80
-0.90 (-1.46%)
At close: Apr 17, 2026
Market Cap2.80B -21.4%
Revenue (ttm)293.23M +2.4%
Net Income111.91M -24.0%
EPS2.43 -24.1%
Shares Out46.00M
PE Ratio25.02
Forward PEn/a
Dividend0.22 (0.36%)
Ex-Dividend Daten/a
Volume36,904
Average Volume97,517
Open61.80
Previous Close61.70
Day's Range59.60 - 61.80
52-Week Range50.00 - 78.60
Beta-0.28
RSI58.88
Earnings DateAug 13, 2026

About HeXun Biosciences

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 45
Stock Exchange Taipei Exchange
Ticker Symbol 6986
Full Company Profile

Financial Performance

In 2025, HeXun Biosciences's revenue was 293.23 million, an increase of 2.38% compared to the previous year's 286.42 million. Earnings were 111.91 million, a decrease of -23.99%.

Financial Statements